The present invention relates to agents and methods for treating autism spectrum disorders, such as Rett Syndrome.

Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA

It is an object of the present invention to identify a novel analog of carbacyclic phosphatidic acid that is a cyclic phosphatidic acid derivative, and to clarify the physiological activity thereof. According to the present invention, a compound represented by the following formula (1) is provided:

##STR00001## wherein R represents a linear or branched alkyl group containing 1 to 30 carbon atoms, a linear or branched alkenyl group containing 2 to 30 carbon atoms, or a linear or branched alkynyl group containing 2 to 30 carbon atoms, and these groups may optionally comprise a cycloalkane ring or an aromatic ring; and M represents a hydrogen atom or a counter cation.

The present invention relates to a method of preparing an aqueous dispersion of nanosized cerium (III) carbonate particles comprising the step of admixing in water a) a water-soluble ammonium cerium (III) salt, b) a water-soluble carbonate, and c) a capping ligand to form an aqueous dispersion of cerium (III) carbonate particles having a resultant z-average particle size is in the range of from 5 nm to 500 nm. The method is useful for the preparation of an additive that is useful in formulations that contain polymer, pigments, dyes, or tints, or a combination thereof, to promote color retention and attenuate unwanted color formation in coatings formed from these formulations.

The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder. ##STR00001##

Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa's will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity. Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability.

The present invention relates to agents and methods for treating autism spectrum disorders, such as Rett Syndrome. This invention addresses the need mentioned above by providing agents and methods for treating or ameliorating symptoms of neurologic diseases, such as autism spectrum disorders and Rett Syndrome. In one aspect, the invention provides a method for treating a neurologic disease associated with one or more mutations in the MECP2 gene.

β-Ketophosphonic acid according to general formula I: ##STR00001##
in which A=an aliphatic C.sub.1-C.sub.18 radical which can be interrupted by —O—, —S—, —CO—O— or —O—CO—C—; n=1, 2, 3 or 4; m=1 or 2; X=absent or a C.sub.1-C.sub.10 radical which can be interrupted by —O—, —S—, —CO—C—, —O—CO—NH— or —CO—NR.sup.1—, wherein R.sup.1 is H or C.sub.1-C.sub.7-alkyl; and PG=a group which can undergo free radical polymerization. The β-ketophosphonic acids are suitable in particular for the preparation of dental materials.

A method for making metal organic frameworks (MOFs) includes the step of dissolving metal salts in deionized water to form first solution, followed by adding a cyclic propyl phosphonic anhydride reagent to the first solution to form a second solution. The second solution is heated to form a reaction mixture containing MOF crystals, and is then cooled. The MOF crystals are filtered therefrom, washed and dried. To make metal organic framework-based thin film nanocomposite membranes, the MOF crystals are mixed with an m-phenylene diamine aqueous solution to form a mixture, which is then poured on a top surface of an ultrafiltration membrane substrate to form a first intermediate membrane structure. The first intermediate membrane structure is dried, and trimesolyl chloride in n-hexane solution is poured thereon to form a second intermediate membrane structure, which is cured to form an MOF-based thin film nanocomposite membrane, which is then rinsed and dried.

Acidic monomer according to Formula I:

##STR00001##

in which A is a linear or branched aliphatic C.sub.1-C.sub.18-hydrocarbon group, which can be interrupted by one or more —O—, —S—, —CO—O—, —O—CO—NH—, —HN—CO—NH— or —CO—NR.sup.1—; R.sup.1 is H or a C.sub.1-C.sub.6 alkyl group; X is absent or is a linear or branched aliphatic C.sub.1-C.sub.10 hydrocarbon group, which can be interrupted by one or more —O—, —S—, —CO—O—, —O—CO—NH—, —HN—CO—NH— or —CO—NR.sup.2—; R.sup.2 is H or a C.sub.1-C.sub.6 alkyl group; PG is a radically polymerizable group, preferably vinyl, allyl, CH.sub.2═CR.sup.3—CO—Y— or R.sup.4O—CO—C(═CH.sub.2)—CH.sub.2—Y—; Y═O or NR.sup.5 or is absent; R.sup.3 is H or CH.sub.3; R.sup.4 is H or a C.sub.1-C.sub.7 alkyl group; R.sup.5 is H or a C.sub.1-C.sub.7 alkyl group; n is 1, 2, 3 or 4; m=1 or 2; p=1, 2 or 3; and q=1, 2 or 3. The monomers are particularly suitable as components of dental material.